All In Biotech

Drug Trial Radar · NCT01459796

Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

Last checked: Nov 20, 2026Latest source record: Jul 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

220

Actual

Start

Nov 2011

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Oct 26, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the safety and tolerability of rilonacept for participants with gout who were initiating allopurinol.

Conditions

  • Gout

Interventions

  • RilonaceptDrug

    Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 52 weeks.

  • PlaceboDrug

    Placebo loading dose followed by placebo injections (2 mL) qw for 52 weeks.

  • AllopurinolDrug

    Allopurinol 50 or 100 mg, orally daily for 52 weeks as background treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Day 1 to Day 392 (Week 56)

Locations

74 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mesa, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Sierra Vista, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Searcy, Arkansas

  • Site not named

    Concord, California

  • Site not named

    La Jolla, California

  • Site not named

    Long Beach, California

  • Site not named

    Whittier, California

  • Site not named

    Denver, Colorado

  • Site not named

    Trumbull, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Clearwater, Florida

  • Site not named

    DeLand, Florida

  • Site not named

    Delray Beach, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Venice, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Coeur d'Alene, Idaho

  • Site not named

    Meridian, Idaho

  • Site not named

    Avon, Indiana

  • Site not named

    Brownsburg, Indiana

  • Site not named

    Evansville, Indiana

  • Site not named

    Bowling Green, Kentucky

  • Site not named

    Elizabethtown, Kentucky

  • Site not named

    Owensboro, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Cumberland, Maryland

  • Site not named

    Hagerstown, Maryland

  • Site not named

    Wheaton, Maryland

  • Site not named

    Fall River, Massachusetts

  • Site not named

    Edina, Minnesota

  • Site not named

    St Louis, Missouri

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.